| 2023年年报 | 2022年年报 | |
|---|---|---|
| 营业收入(元) | ||
| CDMO业务(元) | 63,979,100.00 | 100,249,233.10 |
| 医药制造(元) | 841,568,100.00 | 717,632,113.65 |
| 授权许可(元) | 99,286,800.00 | - |
| 营业成本(元) | ||
| CDMO业务(元) | 40,261,600.00 | 36,758,840.90 |
| 医药制造(元) | 180,892,000.00 | 162,286,469.32 |
| 授权许可(元) | - | - |
| 毛利(元) | ||
| CDMO业务(元) | 23,717,500.00 | 63,490,392.20 |
| 医药制造(元) | 660,676,100.00 | 555,345,644.33 |
| 授权许可(元) | 99,286,800.00 | - |
| 毛利率(%) | ||
| CDMO业务(%) | 37.07 | 63.33 |
| 医药制造(%) | 78.51 | 77.39 |
| 授权许可(%) | - | - |
| 收入构成(%) | ||
| CDMO业务(%) | 6.37 | 12.26 |
| 医药制造(%) | 83.75 | 87.74 |
| 授权许可(%) | 9.88 | - |
| 毛利构成(%) | ||
| CDMO业务(%) | 3.03 | 10.26 |
| 医药制造(%) | 84.30 | 89.74 |
| 授权许可(%) | 12.67 | - |